Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesInfliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis
Modern Rheumatology, 08/21/09
Kageyama Y et al. – Study reports that the reduction of serum IL-23 levels in rheumatoid arthritis (RA) patients was a novel action of infliximab.
Methods- Main objectives of this study were to investigated the effect of infliximab combined with MTX and MTX alone on the serum levels of IL-23 and IL-17 in RA pts:
- Infliximab group- Infliximab combined with MTX was administered to 26 pts
- MTX group- MTX alone was given to 20 pts
- Clinical and laboratory parameters evaluated:
- Disease Activity Scores of 28 joints (DAS28)
- Serum levels of IL-23 and IL-17 at baseline and at 14 and 30 wks after the initial treatment with these drugs
- Single regression analysis performed between the levels of serum IL-23 and other clinical and laboratory parameters at baseline before the initial treatment with infliximab or MTX
- A significant reduction of DAS28 scores observed in both the infliximab and the MTX group at 14 and 30 wks after the initial treatment
- A decrease in serum levels of IL-23 was observed in the infliximab group but not in the MTX group at 14 and 30 wks
- Serum IL-17 levels did not show a significant change during the f/u period
- At baseline, before the initial treatment with infliximab or MTX, serum IL-23 levels showed a significant correlation with DAS28 and the number of swollen joints
Related Articles
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 83%
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Relevance Score: 82%
Monocyte derived interleukin (IL)-23 is an important determinant of synovial Il-17A expression in rheumatoid arthritis
Journal of Rheumatology, 10/05/09
Relevance Score: 81%
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Relevance Score: 80%
New Treatment Combination Promising for Children with Arthritis
MedLinePlus, 11/03/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Benefit-risk assessment of vitamin D supplementation
Osteoporosis International, 12/09/09
Alendronate reduces osteoclast precursors in osteoporosis
Osteoporosis International, 12/09/09
Tacrolimus Therapy for Circinate Balanitis Associated With Reactive Arthritis
Journal of Clinical Rheumatology (JCR), 12/09/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis
Atherosclerosis, 12/09/09
Silica exposure among male current smokers is associated with a high risk of developing ACPA positive rheumatoid arthritis
Annals of Rheumatic Diseases, 12/08/09
MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
Arthritis & Rheumatism, 12/07/09
Sponsor
Article Search
Sponsor